Authorized purpose: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
Clinical role
Adjunctive detection, localization, measurement and longitudinal comparison
Images and patients
CT/CTA · Chest/Lung
Key limitation
Keep in mind: Adjunctive information only; not for use without the original CT series. Both lungs must be in view and the labeled age, asymptomatic population and nodule-size restrictions apply.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/Lung Input: Chest CT in DICOM format with both lungs in the field of view; original CT series must be available. Prior and current examinations support temporal comparison.
Who uses it?Intended users: Radiologists
What does the software produce?Output: CADe overlays and nodule segmentation, longest/shortest and mean diameters, volume, mean HU density, lobar location and prior/current nodule matching with increased, decreased, new, disappeared or unchanged status.
What is its most important limitation?Key limitation: Adjunctive information only; not for use without the original CT series. Both lungs must be in view and the labeled age, asymptomatic population and nodule-size restrictions apply.
Clinical takeaway. Clinical role: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
Evidence takeaway. Evidence from the reviewed source record: K240554 reports separate standalone cohorts for longitudinal nodule matching (98 cases), lobar location (94 scans) and lung/lobe segmentation (22 cases). Nodule detection/segmentation consistency with the predicate was assessed separately.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
Chest CT in DICOM format with both lungs in the field of view; original CT series must be available. Prior and current examinations support temporal comparison.
CADe overlays and nodule segmentation, longest/shortest and mean diameters, volume, mean HU density, lobar location and prior/current nodule matching with increased, decreased, new, disappeared or unchanged status.
Adjunctive information only; not for use without the original CT series. Both lungs must be in view and the labeled age, asymptomatic population and nodule-size restrictions apply.
K240554 reports separate standalone cohorts for longitudinal nodule matching (98 cases), lobar location (94 scans) and lung/lobe segmentation (22 cases). Nodule detection/segmentation consistency with the predicate was assessed separately.
Exact FDA submission
Checked 2026-09-05
Refines baseline ACR 214 cases: 98+94+22 is a sum of test cohorts, not a verified unique-patient total or a new reader diagnostic-sensitivity cohort.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K240554 reports separate standalone cohorts for longitudinal nodule matching (98 cases), lobar location (94 scans) and lung/lobe segmentation (22 cases). Nodule detection/segmentation consistency with the predicate was assessed separately.
FDA source
Exact FDA submission
Checked 2026-09-05
Refines baseline ACR 214 cases: 98+94+22 is a sum of test cohorts, not a verified unique-patient total or a new reader diagnostic-sensitivity cohort.
Matching, lobar localization and Dice segmentation results are not diagnostic nodule-detection sensitivity; no exact-release estimate promoted.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-05
No exact-release specificity estimate established from the reviewed new-feature tests.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K240554 longitudinal nodule matching validation
DesignStandalone comparison of automatic matching against reference nodule pairs
Population98 screening cases with 206 nodule pairs
Medicare National Coverage Determination 210.14 (version effective 2022-02-10) covers annual lung cancer screening with low dose CT under Part B as a preventive service for eligible beneficiaries (age 50-77, asymptomatic, at least 20 pack-years, current smoker or quit within 15 years, with an order and a prior counseling and shared decision-making visit). It requires a board-certified or board-eligible reading radiologist and a facility that uses a standardized lung nodule identification, classification and reporting system. The NCD does not mention AI or nodule-detection software. This is national service-level context, not a determination that this exact product is covered or separately paid. No payment amount or software-specific code was reviewed.
National coverage of the LDCT lung screening service (NCD 210.14); software-specific coverage and payment not established
Medicare (Original Medicare, CMS) · United States · Effective 2022-02-10
The NCD covers the screening service and does not address AI software. It does not prove eligibility, coverage or separate payment for this product, version, patient, site or claim.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Chest CT in DICOM format with both lungs in the field of view; original CT series must be available. Prior and current examinations support temporal comparison.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes InferRead Lung CT.AI as a dedicated post-processing application that can be installed in a healthcare facility or a cloud-based platform. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "a dedicated post-processing application that generates CADe marks as an overlay on original CT scans. The software can be installed in a healthcare facility or a cloud-based platform". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: CADe overlays and nodule segmentation, longest/shortest and mean diameters, volume, mean HU density, lobar location and prior/current nodule matching with increased, decreased, new, disappeared or unchanged status.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: CADe overlays and nodule segmentation, longest/shortest and mean diameters, volume, mean HU density, lobar location and prior/current nodule matching with increased, decreased, new, disappeared or unchanged status.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes InferRead Lung CT.AI as a dedicated post-processing application that can be installed in a healthcare facility or a cloud-based platform. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "a dedicated post-processing application that generates CADe marks as an overlay on original CT scans. The software can be installed in a healthcare facility or a cloud-based platform". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-05Last searched
22Fields reviewed
11Source classes checked
0Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
Stored metadata for Clinical Validation of InferRead Lung CT.AI screened. Live registry page returned only a shell and no readable study details. No exact K240554 linkage or trial results promoted; full record review remains unresolved. The current discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor instructions for use, stored candidate metadata, literature index, trial registry, payer policy, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission
Reviewed labeling and FDA materials do not establish license, hosting, interface or service costs.
Pricing model: Not verified - checked 2026-09-05 - Exact FDA submission
Per-exam versus site licensing and cloud/on-site terms remain unresolved.
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-05 - Exact FDA submission
eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.
AI-Rad Companion (Pulmonary) is image processing software that provides quantitative and qualitative analysis from previously acquired Computed Tomography DICOM images to support radiologists and physicians from emergency medicine, specialty care, urgent care, and general practice in the evaluation and assessment of disease of the lungs. It provides the following functionality: Segmentation and measurements of complete lung and lung lobes Identification of areas with lower Hounsfield values in comparison to a predefined threshold for complete lung and lung lobes Providing an interface to external Medical Device syngo.CT Lung CAD Segmentation and measurements of solid lung nodules. Dedication of found lung nodules to corresponding lung lobe. Correlation of segmented lung nodules of current scan with known priors and quantitative assessment of changes of the correlated data. Identification of areas with elevated Hounsfield values, where areas with elevated versus high opacities are distinguished. The software has been validated for data from Siemens Healthineers (filtered back projection and iterative reconstruction),GE Healthcare (filtered back projection reconstruction), and Philips (filtered back projection reconstruction).Only DI COM images of adult patients are considered to be valid input.
Authorized purpose: Assist radiologists in detecting solid and subsolid pulmonary nodules during review of multivendor multi-detector CT examinations of the chest; the device is an adjunctive first- or second-reader tool.
Authorized purpose: Adjunctive detection of 3-20 mm pulmonary nodules in chest CT examinations for asymptomatic populations, including second-reader use.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.